Tiotropium is the LAMA to Add
For a patient already on Dulera (ICS/LABA) and albuterol rescue, add tiotropium bromide 5 mcg once daily via Respimat inhaler 1, 2. This is the only LAMA with robust evidence and regulatory approval for asthma, specifically studied as add-on therapy to ICS/LABA combinations.
Why Tiotropium
The 2020 NAEPP guidelines conditionally recommend adding LAMA to ICS-LABA in patients ≥12 years with uncontrolled persistent asthma 1. However, essentially all the evidence supporting this recommendation comes from tiotropium studies—the other LAMAs (umeclidinium, glycopyrronium, aclidinium) lack sufficient asthma-specific data 2.
Three major 48-52 week trials (n=1197 patients with severe asthma, mean FEV1 55% predicted) demonstrated that tiotropium 5 mcg daily added to ICS/LABA:
- Reduced exacerbations requiring oral corticosteroids (OR 0.76,95% CI 0.57-1.02), translating to 271 vs 328 per 1000 patients needing rescue steroids 2
- Improved lung function with consistent benefits in trough FEV1 and FVC (high quality evidence) 2
- Enhanced asthma control with small but meaningful improvements 2
- Maintained a favorable safety profile with fewer non-serious adverse events than ICS/LABA alone 2
Clinical Context and Dosing
Your patient is on Dulera, which contains mometasone furoate (ICS) and formoterol (LABA). The evidence base specifically evaluated tiotropium as add-on to existing ICS/LABA therapy 3, 2.
Specific dosing: Tiotropium Respimat 5 mcg (2 puffs of 2.5 mcg) once daily 4, 2. This is distinct from the 18 mcg HandiHaler formulation used in COPD.
Important Caveats
The benefit on quality of life was negligible (AQLQ improvement 0.09, below the 0.5 minimal clinically important difference) 2. The primary value is in reducing exacerbation risk and improving objective lung function, not necessarily symptom burden.
Evidence for serious adverse events was inconsistent (OR 0.60,95% CI 0.24-1.47; I²=76%), though the point estimate favors tiotropium 2. Hospital admissions were too rare to determine benefit 2.
When to Consider This Addition
The 2020 guidelines position LAMA addition as Step 5 therapy—specifically for patients with moderate to severe persistent asthma uncontrolled on ICS-LABA 1. Key indicators include:
- History of ≥1 exacerbation in past 12 months
- Persistent airflow limitation despite ICS/LABA
- Male sex, age <65 years, non-smokers (showed greater FEV1 improvements) 5
- High bronchial hyperresponsiveness 5
Notably, eosinophil levels do NOT predict LAMA efficacy 5, unlike biologics.
Alternative Consideration
The 2020 guidelines note that if LABA is not being used, adding LAMA to ICS alone is conditionally recommended over continuing ICS monotherapy 1. However, your patient is already on the ICS/LABA combination in Dulera, making tiotropium add-on the appropriate next step before escalating to biologics or systemic corticosteroids 1.
What NOT to Do
Do not add LAMA instead of LABA 1. The guidelines conditionally recommend against adding LAMA to ICS over adding LABA to ICS (Grade 1B recommendation) 1. The evidence clearly shows LABA as preferred adjunctive therapy to ICS 6.
The older 2007 EPR-3 guidelines only discussed short-acting anticholinergics (ipratropium) for acute exacerbations, not LAMAs for maintenance 6. The LAMA recommendation represents an evolution in asthma management based on more recent evidence.